

Supplementary Table 3. Baseline characteristics of the patients treated with locoregional therapies (n=3,237)

Variable	Local ablation therapy (n=636, 10.6%)	Transarterial therapy (n=2,493, 41.7%)	Combination therapy* (n=108, 1.8%)
Demographic variable			
Age (years)	60.0 (52.0-68.0)	60.0 (52.0-68.0)	60.0 (52.5-67.0)
Sex (male)	462 (72.6)	1,968 (78.9)	80 (74.1)
Diabetes	161 (25.3)	621 (24.9)	34 (31.5)
Hypertension	187 (29.6)	798 (32.4)	39 (36.1)
Body mass index (kg/m ²)	24.3 (22.2-26.2)	23.7 (21.8-26.0)	24.2 (22.4-26.7)
Smoking	238 (37.7)	1,148 (46.4)	45 (41.7)
Etiology	n=574	n=2,207	n=86
HBV [†]	387 (67.4)	1,558 (70.6)	65 (75.6)
HCV	96 (16.7)	287 (13.0)	9 (10.5)
Alcohol	71 (12.4)	302 (13.7)	10 (11.6)
Others	20 (3.5)	60 (2.7)	2 (2.3)
Performance status [‡]	n=418	n=1,728	n=81
0	384 (91.9)	1,421 (82.2)	75 (92.6)
1	26 (6.2)	245 (14.2)	5 (6.2)
2	6 (1.4)	44 (2.5)	1 (1.2)
3	2 (0.5)	11 (0.6)	0
4	0	7 (0.4)	0
Ascites	n=636	n=2,493	n=108
None	553 (86.9)	1,961 (78.7)	94 (87.0)
Mild	58 (9.1)	364 (14.6)	13 (12.0)
Moderate to severe	25 (3.9)	168 (6.7)	1 (0.9)
Encephalopathy	n=633	n=2,479	n=108
None	624 (98.6)	2,435 (98.2)	107 (99.1)
Mild to moderate (grade 1 or 2)	5 (0.8)	33 (1.3)	1 (0.9)
Severe (grade 3 or 4)	4 (0.6)	11 (0.4)	0
Laboratory variable			
Total bilirubin (mg/dL)	0.9 (0.7-1.4)	1.0 (0.7-1.5)	0.8 (0.5-1.3)
Serum albumin (g/dL)	3.9 (3.4-4.2)	3.7 (3.3-4.1)	3.9 (3.4-4.2)
Alanine aminotransferase (IU/L)	34.0 (22.0-52.0)	37.0 (24.0-58.0)	33.0 (22.0-48.5)
Platelet count (10 ⁹ /L)	110.0 (75.5-152.0)	126.0 (86.0-185.0)	111.0 (77.0-134.5)
Prothrombin time (INR)	1.12 (1.05-1.23)	1.11 (1.04-1.23)	1.12 (1.06-1.19)
Creatinine (mg/dL)	0.90 (0.72-1.00)	0.90 (0.73-1.00)	0.90 (0.79-1.08)
Sodium (mmol/L)	140.0 (138.0-142.0)	139.0 (137.0-141.0)	139.8 (138.0-142.0)
Glucose (mg/dL)	108.0 (94.0-142.0)	110.0 (94.0-143.0)	116.0 (98.5-138.5)
Total cholesterol (mg/dL)	155.5 (133.5-173.0)	152.0 (128.0-178.0)	149.0 (131.0-179.0)
Alpha-fetoprotein (ng/mL)	12.3 (4.9-49.6)	43.3 (8.2-567.3)	12.1 (6.1-49.5)
PIVKA-II (mAU/mL)	28.0 (18.5-56.5)	151.0 (29.5-1,200.0)	32.5 (16.0-89.0)

Supplementary Table 3. Continued

Variable	Local ablation therapy (n=636, 10.6%)	Transarterial therapy (n=2,493, 41.7%)	Combination therapy* (n=108, 1.8%)
Child-Turcotte-Pugh class	n=608	n=2,353	n=99
A	491 (80.8)	1,767 (75.1)	78 (78.8)
B	101 (16.6)	530 (22.5)	20 (20.2)
C	16 (2.6)	56 (2.4)	1 (1.0)
MELD score	8.6 (7.3-10.6)	8.6 (7.3-10.8)	8.5 (7.2-9.9)
MELD-Na score	9.4 (7.7-12.2)	10.0 (8.1-13.1)	9.3 (7.7-11.5)
Tumor variable			
Tumor number	n=636	n=2,490	n=107
1	537 (84.4)	1,417 (56.9)	72 (67.3)
2	81 (12.7)	409 (16.4)	23 (21.5)
3	9 (1.4)	165 (6.6)	5 (4.7)
4	0	60 (2.4)	1 (0.9)
≥5	9 (1.4)	439 (17.6)	6 (5.6)
Maximal tumor diameter (cm)	1.9 (1.5-2.5)	3.0 (2.0-5.0)	2.0 (1.5-2.9)
Portal vein invasion	15 (2.4)	483 (19.4)	14 (13.0)
Hepatic vein invasion	1 (0.2)	98 (3.9)	2 (1.9)
Bile duct invasion	0	48 (1.9)	0
Lymph node metastasis	5 (0.8)	127 (5.1)	2 (1.9)
Distant metastasis	6 (0.9)	148 (5.9)	2 (1.9)
Modified UICC stage	n=633	n=2,484	n=107
Stage I	281 (44.4)	326 (13.1)	32 (29.9)
Stage II	280 (44.2)	937 (37.7)	45 (42.1)
Stage III	62 (9.8)	787 (31.7)	21 (19.6)
Stage IV-A	4 (0.6)	287 (11.6)	7 (6.5)
Stage IV-B	6 (0.9)	147 (5.9)	2 (1.9)
BCLC stage	n=608	n=2,352	n=99
0	169 (27.8)	186 (7.9)	19 (19.2)
A	354 (58.2)	939 (39.9)	52 (52.5)
B	22 (3.6)	406 (17.3)	9 (9.1)
C	46 (7.6)	753 (32.0)	18 (18.2)
D	17 (2.8)	68 (2.9)	1 (1.0)

Values are expressed as median (interquartile range) or number (%).

HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PIVKA-II, protein induced by vitamin K absence-II; MELD, Model for End Stage Liver Disease; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.

*Combination therapy is defined as the combined treatment of local ablation therapy and transarterial therapy; †Patients co-infected with HBV and HCV were also included; ‡Performance status was defined as follows: 0, fully active without symptoms; 1, ambulatory with symptoms; 2, bedridden <50% of the time; 3, bedridden >50% of the time but capable of self-care; 4, bedridden 100% of the time and incapable of self-care.